As we approach the end of 2016, for good or ill, this time of year lends itself to reflection. To look back over these 12 months in research at Children's Hospital of Philadelphia, we've decided to pick 12 of the most popular stories we've brought you in the past year. While any year has its hardships and its triumphs, we're
Cancer genetics and collaboration were big themes in this week’s news featuring research at The Children’s Hospital of Philadelphia. Check out our weekly summary of some of the developments this first week of February.
Pediatric cancer researchers at The Children’s Hospital of Philadelphia believe they have succeeded in their search for a powerful next-generation drug for neuroblastoma tumors with mutations in the anaplastic lymphoma kinase (ALK) gene associated with the cancer.
In 2016, one million or more volunteers may begin enrolling in one of the largest long-term medical research studies ever planned. It aims to inform future therapies targeted to the molecular, environmental, and behavioral factors that contribute to diverse diseases.
The Mossé Laboratory studies the role of the anaplastic lymphoma kinase (ALK) oncogene in the initiation and progression of neuroblastoma, with a focus on developing innovative therapeutic strategies for patients with this often lethal disease.